Impact of Inclisiran on LDL-C Over 18 months in Patients With ASCVD or Risk-Equivalent - ORION-11
Contribution To Literature:
Highlighted text has been updated as of November 14, 2022.
The ORION-11 trial showed that twice yearly inclisiran injection reduced LDL-C by 50%.
The goal of the trial was to evaluate inclisiran compared with placebo among patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk-equivalents. Inclisiran is a small interfering double-stranded RNA that inhibits PCSK9 production.
Patients with ASCVD or ASCVD risk-equivalents were randomized to inclisiran 300 mg injection administered on day 1, day 90, day 270, and day 450 versus placebo.
- Total number of enrollees: 1,617
- Duration of follow-up: 18 months
- Mean patient age: 65 years
- Percentage female: 28%
- Percentage with diabetes: 35%
- ≥18 years of age
- Stable ASCVD or ASCVD risk-equivalent (type 2 diabetes, familial hypercholesterolemia, ≥20% ASCVD risk)
- Elevated low-density lipoprotein cholesterol (LDL-C) (≥70 mg/dl if ASCVD and 100 mg/dl if risk-equivalents) despite maximum tolerated statin therapy
- Prior or planned use of PCSK9 inhibitor
- Major adverse cardiac event within the last 3 months
- Left ventricular ejection fraction ≤30% or New York Heart Association class III-IV symptoms
- Uncontrolled hypertension
- Severe concomitant noncardiovascular disease
- Use of another investigational drug
- Fasting triglyceride >400 mg/ml
Other salient features/characteristics:
- 87.6% had established ASCVD
- 12.4% had ASCVD risk-equivalents
- Mean baseline LDL-C was 112 mg/dl
- 96.2% were on statin therapy at baseline
The primary outcome, mean percent change in LDL-C at 510 days, was -49 in the inclisiran group compared with 4 in the placebo group (p < 0.0001). This was a time-averaged 50% reduction in LDL-C for inclisiran versus placebo.
- Exploratory cardiovascular endpoint: 7.8% with inclisiran vs. 10.3% with placebo
- Treatment-emergent adverse event: 83% with inclisiran vs. 82% with placebo
- Serious adverse event: 22% with inclisiran vs. 23% with placebo
- Protocol defined skin event: 4.7% with inclisiran vs. 0.5% with placebo
- No sign of liver, kidney, or muscle toxicity
Primary prevention cohort of ORION-11 (n = 203):
- Mean percent change in LDL-C at 510 days: −41.9 in the inclisiran group compared with +1.8 in the placebo group (p < 0.0001). This was a time-averaged −41.0% reduction in LDL-C for inclisiran vs. placebo (p < 0.0001).
Pooled analysis of ORION-9, ORION-10, and ORION-11:
- Mean percent change in LDL-C at 510 days: -51 in the inclisiran group compared with 4 in the placebo group (p < 0.0001). This was a time-averaged 52% reduction in LDL-C for inclisiran vs. placebo.
- At least one treatment-emergent adverse event: 78.0% with inclisiran vs. 77.3% with placebo
- At least one serious treatment-emergent adverse event: 20.4% with inclisiran vs. 23.0% with placebo
- Prespecified exploratory cardiovascular event: 7.1% with inclisiran vs. 9.4% with placebo
Among patients with ASCVD or ASCVD risk-equivalents, twice yearly inclisiran injection resulted in a significant reduction in LDL-C. This was well tolerated with no sign of liver, muscle, or kidney toxicity. The use of a small interfering double-stranded RNA is a novel approach to management of LDL-C. Clinical event-powered randomized trials are needed.
Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 2022;Nov 4:[Epub ahead of print].
Ray KK, Wright RS, Kallend D, et al., on behalf of the ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients With Elevated LDL Cholesterol. N Engl J Med 2020;382:1507-19.
Presented by Dr. R. Scott Wright at the American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology (ACC 2020/WCC), March 28, 2020.
Presented by Dr. Kausik K. Ray at the European Society of Cardiology Congress, Paris, France, September 2, 2019.
Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Prevention, Lipid Metabolism, Nonstatins, Novel Agents, Primary Hyperlipidemia, Statins
Keywords: acc20, ACC Annual Scientific Session, ESC Congress, ESC 19, Atherosclerosis, Cholesterol, LDL, Diabetes Mellitus, Type 2, Dyslipidemias, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemia Type II, Metabolic Syndrome, Proprotein Convertases, Primary Prevention, RNA, Double-Stranded, RNA, Small Interfering
< Back to Listings